Current Management of Locally Advanced Esophageal and Esophagogastric Junction Cancers: Clinical Evidence and Evolving Strategies.

Although the primary endpoint of 3-year (progression-free survival) PFS did not reach statistical significance (55.8% vs. 44.2%; HR = 1.38; p = 0.16), the survival benefit supported the shift toward preoperative chemotherapy in this population [ 32 , 33 ].

also in 111,027 other papers